



February 1, 2017

To,

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Dear Sirs,

Sub: Unaudited financial results for the quarter ended December 31, 2016

(Scrip Code: RPGLIFE / 532983)


Please find enclosed herewith a copy of Unaudited Financial Results of the Company for the quarter ended December 31, 2016 which was approved by the Board of Directors at its meeting held on February 1, 2017 along with the Limited Review Report by the Statutory Auditors of the Company.

The meeting commenced at 3.00 p.m. and concluded at 5.15 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shrambekar

Head - Legal & Company Secretary



Encl: As above



RPG LIFE SCIENCES LIMITED

Rs. In Lakhs

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2016						
Particulars	3 months ended			9 months ended		Year ended
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
	Unaudited			Unaudited		Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,454	7,638	7,202	22,615	20,572	27,454
(b) Other Operating Income	199	222	115	641	330	478
Total Income from Operations (Net)	6,653	7,860	7,317	23,256	20,902	27,932
2. Expenses						
(a) Cost of Materials Consumed	1,119	1,320	1,611	4,473	4,716	6,025
(b) Purchases of Stock-in-Trade	1,239	1,560	741	4,585	2,400	3,360
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(191)	(44)	(74)	(985)	(216)	(241)
(d) Employee Benefits Expense	1,971	1,863	2,017	5,653	5,591	7,413
(e) Depreciation and Amortisation Expense	326	239	247	833	764	1,015
(f) Other Expenses	2,048	2,494	2,257	7,119	6,563	9,027
Total Expenses	6,512	7,432	6,799	21,678	19,818	26,599
3. Profit from Operations before Other Income, Finance Costs and Exceptional Items	141	428	518	1,578	1,084	1,333
4. Other Income	11	18	4	47	77	78
5. Profit from Ordinary Activities before Finance Costs and Exceptional Items	152	446	522	1,625	1,161	1,411
6. Finance Costs	97	18	55	155	224	249
7. Profit from Ordinary Activities after Finance Costs but before Exceptional Items	55	428	467	1,470	937	1,162
8. Exceptional Items - Profit on sale of Biotech Business Unit [Refer Note 4]	-	738	-	738	-	-
9. Profit from Ordinary Activities before Tax	55	1,166	467	2,208	937	1,162
10. Tax Expense						
a. Current Tax	12	250	100	475	197	224
b. MAT Credit Entitlement	(12)	(250)	(100)	(475)	(197)	(224)
c. Deferred Tax	-	141	-	141	-	-
11. Net Profit for the period	55	1,025	467	2,067	937	1,162
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						12,036
14. Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	0.33	6.20	2.82	12.50	5.67	7.03
(b) Diluted	0.33	6.20	2.82	12.50	5.67	7.03



Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India
 Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127
 E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com
 CIN : L24232MH2007PLC169354





RPG LIFE SCIENCES LIMITED


Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 1st February, 2017.
2. The results for the quarter ended 31st December, 2016 have been subjected to limited review by the statutory auditors of the Company.
3. The Company is exclusively engaged in the pharmaceuticals segment.
4. Pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of Biotech Business Unit, as a going concern on a slump sale basis, at a consideration of Rs. 2,487 lakhs. The sale consideration had been received on July 6, 2016 (closing date). The gain realised from the aforesaid sale of Biotech Business Unit amounting to Rs. 738 lakhs had been disclosed as an exceptional item in the financial results of the previous quarter. The same has been considered as discontinuing operations in accordance with Accounting Standard - 24 - "Discontinuing Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	3 months ended			9 months ended		Rs. In Lakhs
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	Year ended
	Unaudited					Audited
a) Net Sales	-	-	667	643	1,594	2,437
b) Direct Expenses	-	(7)	547	489	1,553	2,114
c) Profit/(Loss) from ordinary activities before tax	-	7	120	154	41	323
d) Tax Expense (net off MAT Credit Entitlement)	-	-	-	-	-	-
e) Net Profit/(Loss) from ordinary activities after tax (c-d)	-	7	120	154	41	323
f) Profit on sale of Biotech Business Unit	-	738	-	738	-	-
g) Tax Expense [net of MAT credit entitlement] on f) above	-	-	-	-	-	-
h) Profit on sale of Biotech Business Unit (net of tax) (f-g)	-	738	-	738	-	-
i) Net Profit/(Loss) from discontinuing operations (e+h)	-	745	120	892	41	323

5. Pursuant to an Asset Purchase Agreement (APA) dated July 27, 2016 for purchase of Trademarks on assignment/perpetual license basis and other assets specified in the said APA from Sun Pharmaceutical Industries Limited (including its subsidiary, Sun Pharma Laboratories Limited) the company has capitalised the aforesaid intangible assets amounting to Rs. 4,273 lakhs on October 21, 2016 (closing date).
6. During the quarter ended December 31, 2016, the Company has allotted 2,910 equity shares of Rs. 8 each pursuant to exercise of stock options by an employee under "2005 Employee Stock Option Plan".
7. Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited


CT Renganathan
Managing Director
Mumbai, 1st February, 2017



The Board of Directors
RPG Life Sciences Limited
RPG House
463, Dr. Annie Besant Road,
Worli, Mumbai – 400 030

1. We have reviewed the unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended December 31, 2016 which are included in the accompanying 'Statement of Standalone Unaudited Results for the quarter and nine months ended December 31, 2016' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes
Firm Registration Number: 301056E
Chartered Accountants



Sumit Seth
Partner
Membership Number 105869

Mumbai
1st February, 2017